Colorectal Cancer | Specialty

Adagrasib/Cetuximab Combo in KRAS G12C+ CRC Under Exploration

July 1st 2021

The combination of adagrasib and cetuximab is being investigated in patients with previously treated, advanced, KRAS G12C–mutant colorectal cancer in the international, phase 3 KRYSTAL-10 study.

Nivolumab/Ipilimumab Approved in Europe for dMMR or MSI-H Metastatic Colorectal Cancer

June 29th 2021

The European Commission has approved the combination of nivolumab plus ipilimumab for use in adult patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following previous fluoropyrimidine-based combination chemotherapy.

Sequencing Therapy in Metastatic CRC Is a Marathon, Not a Sprint

June 24th 2021

Actionable mutations identified in colorectal cancer have contributed significantly to the expansion of the therapeutic options available for patients with metastatic disease.

KRAS G12C Inhibitors in mCRC

June 22nd 2021

A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.

Future Directions in mCRC

June 22nd 2021

Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.

Dr. Jones on the Clinical Utility of Pembrolizumab in MSI-H CRC

June 21st 2021

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

Dr. Bekaii-Saab on the Uptake of Precision Medicine in CRC

June 17th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Dr. Jones on the Importance of Testing for Microsatellite Instability in CRC

June 15th 2021

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.

EGFR Therapy for mCRC: Dermatologic Toxicity

June 15th 2021

Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.

Later-Line Treatment Options for mCRC

June 15th 2021

Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.

Dr. Strickler on Selecting Between TAS-102 and Regorafenib in CRC

June 14th 2021

John H. Strickler, MD, discusses factors to consider when selecting between trifluridine/tipiracil and regorafenib for the treatment of patients with colorectal cancer.

Regorafenib/Nivolumab Found to be More Effective in Japanese Population vs North American in CRC

June 9th 2021

Real-World Analysis on Second-Line Cetuximab in mCRC Reveals Factors Linked With Longer Time on Treatment, OS

June 9th 2021

In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

Sequencing Anti-EGFR Therapy in mCRC

June 8th 2021

The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.

Changes in Cetuximab Dosing Schedule in mCRC

June 8th 2021

Reactions to recent changes approved by the FDA to the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Panitumumab Plus 5-FU/Leucovorin Maintenance Improves PFS in RAS Wild-Type Metastatic CRC

June 8th 2021

The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.

Trastuzumab Deruxtecan Maintains Antitumor Activity in HER2+ mCRC

June 7th 2021

Final results of the DESTINY-CRC01 trial were consistent with primary analysis, establishing the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-overexpressing metastatic colorectal cancer.

mFOLFOXIRI/Cetuximab Combo Improves Depth of Response in RAS Wild-Type mCRC

June 7th 2021

Cetuximab added to mFOLFOXIRI induced superior depth of response than mFOLFOXIRI plus bevacizumab in treatment-naïve patients with RAS wild-type metastatic colorectal cancer.

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC

June 7th 2021

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Lenvatinib Plus Pembrolizumab May Increase OS Rates in Advanced Colorectal Cancer

June 4th 2021

Some patients with previously treated advanced colorectal cancer responded to treatment with lenvatinib plus pembrolizumab.